CRISPR Therapeutics closes public offering of USD 200m
CRISPR Therapeutics AG (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, announced on September 20, 2018 the pricing of a public offering of 4,210,526 of its shares at an offering price of $47.50 per share. The gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, are estimated to be approximately $200 million.
Goldman Sachs & Co. LLC, Piper Jaffray & Co., Barclays Capital Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. Guggenheim Securities, LLC and Needham & Company, LLC are acting as co-managers for the offering. Goodwin Procter LLP advises CRISPR Therapeutics as to US law, VISCHER AG as to Swiss law. The team at VISCHER is led by Matthias Staehelin (Partner) with Angelo Imperiale (Associate), both Corporate.